Prognostic Impact of Tumor-Infiltrating Immune Cells on Efficacy of Neoadjuvant Chemotherapy in Patients with Advanced or Metastatic Ovarian Cancer: A Retrospective Study

Background:Tumor-infiltrating immune cells (TIICs) are implicated in the survival of ovarian cancer (OVCA) patients, but their prognostic significance in advanced or metastatic OVCA patients treated with neoadjuvant chemotherapy (NCAT) has not been well documented, particularly in the Chinese population. Material/Methods:A total of 31 advanced or metastatic OVCA patients who underwent NACT were included.The density and positive rate of TIICs within cancer cell nests and in cancer stroma were explored.The correlations of pre-or post-NACT TIICs with the efficacy of NACT and the changes in TIIC subpopulation with NACT were examined. Results:Compared with patients with partial benefit from NACT, significantly decreased pre-NACT intratumoral CD68 + CD163 + cells (P=0.0043) and increased pre-NACT intratumoral CD56 + cells (P=0.038) were observed in patients with benefit.The high level of pre-NACT intratumoral CD68 + CD163 -M1 macrophage (P=0.075) and stromal CD3 + PD-1 + cells (P=0.085)predicated improved progression-free survival, respectively.Increased post-NACT stromal CD68 + CD163 -M1 macrophage (P=0.01),stromal CD8 + T cells (P=0.073), and stromal CD8 + PD-1 + cells (P=0.072) were associated with benefit from NACT.Moreover, NACT increased intratumoral CD3 + (P=0.031),CD8 + (P=0.031), and CD3 + CD8 + cells (P=0.031). Conclusions:High intratumoral CD68 + CD163 -and stromal CD3 + PD-1 + cells pre-NACT predicted good prognosis.Intratumoral CD3 + , CD8 + , and CD3 + CD8 + cells were increased after NACT.Evaluation of immune profiles may help to identify patients who might benefit from NACT and allow us to further stratify advanced or metastatic OVCA patients treated with NACT for disease management.